Questions, answered plainly.

No. Peptides Uncensored is an educational research atlas. Nothing here is medical advice, a diagnosis, a prescription or a protocol for you, and reading it does not create a doctor-patient relationship.

Decisions about any drug belong with a licensed clinician who knows your history, your medications and your lab results.

Read the full disclaimer

Because the numbers are already everywhere, usually with no context. We would rather show where a number comes from and how much weight it can bear.

Every figure is labeled as an FDA label dose, a clinical trial range or a commonly reported range. Showing a number describes the landscape. It is not an endorsement and not a dose for you.

How dose labels work

It is the range that repeats across research-community discussion: forums, clinic handouts and anecdotal logs. Nobody has validated it in a trial.

Repetition is not evidence. It is repetition. These ranges get a dashed amber label so they never look like FDA label or trial figures.

A: multiple adequate human RCTs and/or FDA approval for a defined indication. B: human RCTs exist but narrow, early, or not approved for the popular use. C: human data thin (pilots, uncontrolled, or none completed), with strong animal data and large anecdotal volume. D: mechanism speculation, marketing, or almost no useful human signal.

A grade describes evidence. It is not a safety rating, not a recommendation and not permanent.

The full grading method

A stack is two or more compounds used in the same period, usually from separate vials with separate schedules. A blend is several compounds pre-mixed in one vial at a fixed ratio, such as GLOW (GHK-Cu, BPC-157, TB-500) or KLOW (the same plus KPV).

The difference matters for the math and the unknowns. In a blend, every draw delivers all components at once, so none can be adjusted on its own, and the mix itself has never been tested in a trial.

Stacks and blends

It depends on what “legal” means, and the honest answer is narrower than most sellers imply. In the US, unapproved peptides are not approved for human use. They are often sold labeled “for research use only,” which is a legal posture, not a safety or quality standard.

In April 2026, FDA removed 12 peptides from its Category 2 compounding-risk list. In July 2026, an FDA advisory committee recommended six of them (BPC-157, KPV, TB-500, MOTS-c, epitalon and semax) for the 503A bulks list and voted against emideltide (DSIP). Those votes are recommendations. Until FDA completes notice-and-comment rulemaking, compounding them from bulk is not authorized.

Laws differ outside the US. This is a summary, not legal advice.

The 2026 compounding timeline

Many compounds in this atlas are prohibited. WADA's S0 category covers substances with no current approval for human therapeutic use, including drugs still in clinical development, and it names BPC-157 explicitly. GHRH analogues such as sermorelin and tesamorelin, and growth hormone secretagogues such as ipamorelin, are named under S2. So are thymosin beta-4 and its derivatives, including TB-500. MOTS-c is named under S4.

IV infusions over 100 mL per 12 hours are prohibited too, outside hospital treatment or clinical investigation. Each dossier shows WADA status, but the list changes every year. Confirm with your federation or national anti-doping organization.

Approved semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound) are made under FDA-inspected manufacturing and dosed from their labels. Compounded versions are not FDA-approved and are not reviewed for safety or effectiveness before they are dispensed.

During the shortages, pharmacies were allowed to compound copies. FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025, so mass compounding of copies is no longer permitted. “Personalized” compounded versions, with altered doses or added ingredients, are legally contested.

No. Anabolic steroids are testosterone and its synthetic relatives: fat-soluble molecules built on a four-ring backbone that act mainly through receptors inside the cell. Peptides are chains of amino acids that mostly act on receptors at the cell surface.

The confusion comes from overlapping audiences, since growth-hormone peptides get sold into the same gym culture. Different chemistry does not mean lower risk. It means different questions.

Usually a lot. Stomach acid and digestive enzymes break most peptides apart, so very little of a swallowed dose reaches the blood. Oral semaglutide works only with an absorption enhancer, and its label puts oral bioavailability at roughly 0.4–1%.

Claims that a research peptide is “orally stable” usually rest on lab tests in simulated gastric juice, not on blood levels measured in people.

Routes compared

Every dossier and explainer carries a last-reviewed date. The whole atlas is reviewed at least every three months, and sooner when a trial reads out, a label changes, FDA acts or the WADA list updates.

Use the corrections form on the About page, or email dave@peptidesuncensored.com. A useful report names the page, the claim you think is wrong, and a source (ideally a PubMed ID, an FDA label or a trial registry number).

Factual errors are corrected, and significant changes are noted on the page.

Corrections form